The effect of HDAC6 inhibitors on cell viability, proteasome activity, and pan-MHC-I antigen presentation was determined using CD138+ cells isolated from the bone marrow of patients with multiple myeloma with treatment-refractory disease. Here, HDAC6 is linked to plasma cell myeloma.